/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Equillium Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.85 0.0142(1.42%) EQ at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 0.812
Highest Today 0.885
Today’s Open 0.8401
Prev. Close 0.8593
52 Week High 2.35
52 Week Low 0.27
Day’s Range: Low 0.812 High 0.885
52-Week Range: Low 0.27 High 2.35
1 day return -
1 Week return -3.53
1 month return -39.04
3 month return -49.55
6 month return +134.08
1 year return +21.91
3 year return -48.05
5 year return -82.01
10 year return -

Institutional Holdings

Decheng Capital LLC 7.47

Takeda Pharmaceutical Co Ltd 3.07

Vanguard Group Inc 1.39

Cota Capital Management, LLC 0.95

Vanguard Total Stock Mkt Idx Inv 0.94

Renaissance Technologies Corp 0.46

abrdn Life Sciences Investors 0.38

Geode Capital Management, LLC 0.33

Vanguard Institutional Extnd Mkt Idx Tr 0.29

Citadel Advisors Llc 0.22

Callan Capital, LLC 0.17

Fidelity Extended Market Index 0.17

UBS Group AG 0.14

State Street Corp 0.10

AlphaCore Capital LLC 0.09

PGIM Quantitative Solutions US Micro Cap 0.07

Prudential Financial Inc 0.07

Fidelity Total Market Index 0.06

Northern Trust Corp 0.06

Commonwealth Equity Services Inc 0.04

Fidelity Series Total Market Index 0.04

Baader Bank INC 0.04

Spartan Extended Market Index Pool F 0.03

Vanguard Instl Ttl Stck Mkt Idx Tr 0.03

NT Ext Equity Mkt Idx Fd - NL 0.03

Ground Swell Capital, LLC 0.03

Northern Trust Extended Eq Market Idx 0.03

NT Ext Equity Mkt Idx Fd - L 0.03

Susquehanna International Group, LLP 0.03

Apollon Wealth Management, LLC 0.02

TRITONPOINT WEALTH LLC 0.02

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.02

Virtu Financial LLC 0.02

Fidelity Nasdaq Composite Index 0.02

Spartan Total Market Index Pool G 0.02

Vanguard U.S. Eq Idx £ Acc 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

State St US Extended Mkt Indx NL Cl C 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

State St US Ttl Mkt Indx NL Cl A 0.00

Market Status

Strong Buy: 0

Buy: 0

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 52.33 M

PB Ratio 1.6924

PE Ratio 0.0

Enterprise Value 19.99 M

Total Assets 25.60 M

Volume 686454

Company Financials

Annual Revenue FY23:42632000 42.6M, FY22:15759000 15.8M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:15759000 15.8M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-8220000 -8.2M, FY22:-107707000 -107.7M, FY21:-38980000 -39.0M, FY20:-29768000 -29.8M, FY19:-25577000 -25.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:12161000 12.2M, Q2/2024:13853000 13.9M

Quarterly Profit Q3/2025:-28000 -0.0M, Q2/2025:-32000 -0.0M, Q1/2025:-33000 -0.0M, Q3/2024:12161000 12.2M, Q2/2024:13818000 13.8M

Quarterly Net worth Q3/2025:-4230000 -4.2M, Q2/2025:-5739000 -5.7M, Q1/2025:-8654000 -8.7M, Q3/2024:-7000 -0.0M, Q2/2024:468000 0.5M

Fund house & investment objective

Company Information Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Organisation Biotechnology

Employees 35

Industry Biotechnology

CEO Mr. Bruce D. Steel C.F.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow